The U.S. Patent and Trademark Office has confirmed that MedTrace’s way of producing and dosing small volumes of ¹⁵O-water with high precision to patients before a PET scan is unique, consequently granting MedTrace a patent. The new patent is a testament to the company’s impressive innovation capabilities, says COO and U.S. President, Rune Wiik Kristensen.
Pharma and device company MedTrace aims to make the PET tracer ¹⁵O-water clinically available to healthcare professionals, and today, the company announces that it has added an important product patent to its portfolio, protecting a key component in the company’s ¹⁵O-water technology.
The new patent protects how the company’s automated manufacturing system, P3 MT-100, produces and doses the required small volumes of ¹⁵O-water with high precision to patients before a PET scan.
“¹⁵O-water PET is the gold standard for non-invasive measurements of blood flow in the various regions and organs of the body. The high precision of delivery accomplished by the P3 MT-100 allows us to both evaluate the microcirculation in even higher detail and make sure these measurements are automatically and reproducibly obtained across PET scanners from different vendors,” says Jens Sorensen, MD, professor at Aarhus University (DEN) and Uppsala University (SWE) and co-founder of MedTrace.
Rune Wiik Kristensen, COO and U.S. President at MedTrace, adds that:
“The patent is a testament to MedTrace’s impressive innovation capabilities and it is satisfying to see our technology, the company’s core business, well protected.”
MedTrace’s automated manufacturing system, P3 MT-100, is in use at several hospitals around the world as part of the company’s Phase 3 Clinical Trial, which seeks to evaluate the diagnostic accuracy and safety of ¹⁵O-water as a myocardial perfusion PET imaging agent.
The recently granted product patent is an important addition to MedTrace’s steadily growing patent portfolio which protects the company’s ¹⁵O-water technology as well as clinical uses thereof.
Forward-looking statement
This news release by MedTrace Pharma A/S (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. The company offers no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
About MedTrace Pharma A/S
MedTrace Pharma A/S is a development-stage pharma and device company and an innovator in PET diagnostic imaging. The company is working on a solution to help healthcare professionals diagnose patients better and faster via ¹⁵O-water PET, the gold standard perfusion tracer.
MedTrace focuses on PET imaging technologies with a particular emphasis on blood flow and perfusion quantification. The company has a late-stage pipeline including ¹⁵O-water as a radiopharmaceutical and aQuant as a medical device software (under development) for the image analysis and quantification of blood flow and perfusion data from cardiac PET scans.
